Prevalence of hepatitis A, B and C in the flemish population

European Journal of Epidemiology

Volumn 13, Issue 3, 1997, Pages 275-280

  Beutels, M ^a,c   Van Damme, P ^a,c   Aelvoet, W ^c   Desmyter, J ^c   Dondeyne, F ^c   Goilav, C ^c   Mak, R ^c   Muylle, L ^c   Pierard, D ^c   Stroobant, A ^c   Van Loock, F ^c   Waumans, P ^c   Vranckx, R ^b,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Institute of Hygiene and Epidemiology of Brussels   (Belgium)

^c Hepat Scientific Steering Committee ^*  (Belgium)

Author keywords

Flemish population; Hepatitis A (HAV); Hepatitis B (HBV); Hepatitis C (HCV); Prevalence study

Indexed keywords

ARTICLE; BELGIUM; HEALTH CARE POLICY; HEPATITIS A; HEPATITIS B; HEPATITIS C; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; BELGIUM; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES;

EID: 8544253208     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007393405966     Document Type: Article

References (21)

1. Devroey D, Van Casteren V, Vranckx R. Incidence of acute viral hepatitis in Belgium: Results of the General Practionars Sentinel Survey 1991-1992, report, Institute for Hygiene and Epidemiology, 1994 (in Dutch).
2. Meheus A. Risk of hepatitis B in adolescence and young adulthood. Vaccine 1995; 13 (suppl): 31-34.
3. Vranckx R, De Decker H, Cole J, Muylle L, Peetermans M. Hepatitis A virus antibodies (anti-HAV) in different populationgroups in the Antwerp region (in Dutch). Belg Arch Soc Gen, Hyg, Arb en Ger Gen 1981; 39: 636-642.
4. Vranckx R, Muylle L. Hepatitis A virus antibodies in Belgium: relationship between prevalence and age. Infection 1990; 18(6), 48/364-50/366.
5. Goudeau A, Bruguera M, Desmyter J, et al. Epidemiology and eradication strategy for hepatitis B in Europe. Vaccine 1990; 8 (suppl): 113-116.
6. Deinhardt F, Zuckerman AJ. Immunization against hepatitis B: Report of a WHO meeting on viral hepatitis in Europe. J Med Virol 1985; 17: 209-215.
7. Bytchenko B. Viral hepatitis in the European region. Rep WHO Technical Advisory Group on Viral Hepatitis, Copenhagen, 2-6 December 1985.
8. Margolis H, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Sem. Liver Dis 1991; 11: 84-92.
9. Vranckx R, Walckiers D, Stroobant A, Thiers G. Sero epidemiological characteristics of hepatitis C encountered in general practice in Belgium. Eur J Clin Microbiol Infect Dis 1992; 11: 62-64.
10. Vranckx R. Sexual transmission of hepatitis C virus. BMJ 1991; 303: 783 (Letter).
11. Goilav C, Todts S, Vercauteren G, Gigase P, Piot P. Increasing prevalence rates of anti- HCV antibodies by duration of drug injecting behaviour in a group of injecting drug users in Antwerp. 5th National Forum on Aids, Hepatitis, and Other Blood-borne Diseases, Atlanta, 29 March 1992-1 April (abstract No. P 14), p 37.
12. Kane MA, Clements J, Hu D. Hepatitis B. In: Jamison DT, Mosley WH, Measham AR, Bobadillo J (eds), Disease control priorities in developing countries. A World Bank Book. New York: Oxford University Press 1993: 321-330.
13. Populationstatistics 1993, No. 2 of the National Institute of Statistics, Ministery of Economic Affairs 1993; 2: 111-159 (in Dutch).
14. Prodinger WM, Larcher C, Sölder BM, Geibler D, Dierich MP. Hepatitis A in Western Austria: The epidemiological situation before the introduction of active immunisation. Infection 1994; 22(1): 53-55.
15. Iwarson S. Strategies for immunization against hepatitis B in Western Europe. Vaccine 1993; 11 (suppl): 18-20.
16. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. NEJM 1980; 303: 833-841.
17. Perillo RP, Parker ML, Campbell C, et al. Prevaccination screening of medical and dental students: Should low levels of antibody to hepatitis B surface antigen preclude vaccination? JAMA 1983; 250: 2481-2484.
18. Hanson M, Polesky HF. Prevalence of anti-HBc in anti-HBs positive individuals: Implications for selecting vaccine candidates. Am J Clin Pathol 1984; 82: 716-719.
19. Kessler HA, Harris AA, Payne JA, et al. Antibodies to hepatitis B surface antigen as the sole hepatitis B marker in hospital personnel. Ann Intern Med 1985; 103: 21-26.
20. Werner BG, Dienstag JL, Kuter BJ, et al. Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccination. Ann Intern Med 1985; 103: 201-205.
21. Beutels Ph, Tormans G, Van Damme P, Van Doorslaer E. Routine vaccination against hepatitis B in Flanders: cost-effective? (in Dutch). Tijdschr Soc Gezondheidsz 1996; 74: 270-279.